Ikarian Capital, LLC Bridge Bio Pharma, Inc. Call Options Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$23.0 - $31.04 $8.82 Million - $11.9 Million	-383,400 Reduced 98.46%	6,000 $151,000
Q1 2024 May 15, 2024	BUY	$27.35 - $40.45 $10.7 Million - $15.8 Million	389,400 New	389,400 $12 Million
Q3 2023 Nov 14, 2023	SELL	$16.89 - $35.01 $20.7 Million - $42.9 Million	-1,226,746 Reduced 99.75%	3,054 $80,000
Q2 2023 Aug 14, 2023	BUY	$13.29 - $18.01 $9.04 Million - $12.3 Million	680,200 Added 123.76%	1,229,800 $21.2 Million
Q1 2023 May 15, 2023	BUY	$7.17 - $18.55 $3.94 Million - $10.2 Million	549,600 New	549,600 $9.11 Million
Q2 2022 Aug 12, 2022	BUY	$5.21 - $12.14 $1.04 Million - $2.43 Million	200,000 New	200,000 $1.82 Million
Q1 2022 May 13, 2022	SELL	$7.34 - $17.16 $734,000 - $1.72 Million	-100,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.38 - $53.41 $1.14 Million - $5.34 Million	100,000 New	100,000 $1.67 Million
Q3 2020 Nov 16, 2020	SELL	$27.2 - $42.19 $856,800 - $1.33 Million	-31,500 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$22.22 - $35.69 $699,930 - $1.12 Million	31,500 New	31,500 $1.03 Million

291

171M

10.4M

2.37M

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $3.85B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.